Skip to content

Pfizer Asks FDA to Clear Another Booster For Older Adults

  • Boosters helped recipients fend off delta, omicron variants
  • Fourth dose could help better shield more vulnerable adults
A vial of Pfizer-BioNTech Covid-19 vaccine.

A vial of Pfizer-BioNTech Covid-19 vaccine.

Photographer: Dwayne Senior/Bloomberg
Updated on

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional Covid-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes. 

The New York-based drugmaker and its German partner BioNTech SE said on Tuesday that they have sought an emergency-use authorization from the Food and Drug Administration for a second booster of their vaccine, Comirnaty, for people 65 and older who have already received a booster of any of the authorized Covid-19 vaccines.